- Home
- RPRX vs STLA Comparison
RPRX vs STLA Comparison
Compare RPRX & STLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RPRX | STLA |
|---|---|---|
| Founded | 1996 | 2021 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 22.0B | 19.4B |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RPRX | STLA |
|---|---|---|
| Price | $55.07 | $7.39 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $51.40 | $11.59 |
| AVG Volume (30 Days) | 3.2M | ★ 15.9M |
| Earning Date | 05-06-2026 | 02-26-2026 |
| Dividend Yield | 1.90% | ★ 7.50% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.67 | N/A |
| Revenue | ★ $2,378,193,000.00 | N/A |
| Revenue This Year | $38.63 | $7.18 |
| Revenue Next Year | $4.73 | $3.50 |
| P/E Ratio | $82.04 | ★ N/A |
| Revenue Growth | ★ 5.06 | N/A |
| 52 Week Low | $33.37 | $6.28 |
| 52 Week High | $55.86 | $12.22 |
Technical Indicators
Market Signals| Indicator | RPRX | STLA |
|---|---|---|
| Relative Strength Index (RSI) | 65.22 | 43.82 |
| Support Level | $35.35 | $7.08 |
| Resistance Level | N/A | $7.91 |
| Average True Range (ATR) | 1.16 | 0.22 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 78.31 | 31.33 |
Price Performance
Historical ComparisonAbout RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About STLA Stellantis N.V.
Stellantis was created out of the merger of US-based Fiat Chrysler Automobiles and French-based Peugeot in January 2021, resulting in the fourth-largest automotive original equipment manufacturer by vehicle sales. In 2024 it sold 5.5 million vehicles, 47%, 26% and 17% in Europe, North America, and South America, respectively. Its brands include Fiat, Jeep, Chrysler, Ram, Peugeot, Citroën, Opel, Alfa Romeo, and Maserati.